Review of international experience of application of various forms of antimetabolites - folic acid antagonists in rheumatoid arthritis

Обзор мирового опыта применения различных форм антиметаболита – антагониста фолиевой кислоты при ревматоидном артрите
Gulzhan Alibekova 1, Saule Abisheva 1
More Detail
1 JSC “Astana Medical University” Astana, Kazakhstan
J CLIN MED KAZ, Volume 4, Issue 34, pp. 30-33.
OPEN ACCESS 5119 Views 3878 Downloads
Download Full Text (PDF)

ABSTRACT

This review article presents the results of randomized, multicenter studies on the use of various forms of methotrexate in the world. The analysis of effectiveness and safety, as well as the side effects of the drug has been conducted. According to the review of the articles subcutaneous forms of methotrexate have better bioavailability than the oral forms, even when starting with a low dose. Accordingly high doses are absorbed better. The gradual increase in subcutaneous dose provides linear gain in effect, unlike the oral forms. The article is recommended to rheumatologists, physicians and general practitioners.
Keywords: rheumatoid arthritis, methotrexate, effectiveness, side effects

CITATION

Alibekova G, Abisheva S. Review of international experience of application of various forms of antimetabolites - folic acid antagonists in rheumatoid arthritis. Journal of Clinical Medicine of Kazakhstan. 2014;4(34):30-3.

REFERENCES

  • Nasonov E.L. Revmatologija: Klinicheskie rekomendacii (Rheumatology: Treatment guidelines), M.: GJeOTAR-Media, 2010, 90 p.
  • Marc C. Hochberg. Rheumatology, 6 edition. Elsevier Mosby, 2014, Р.48-94.
  • Mercado F.B., Marshall R.I., Klestov A.C., Bartold P.M. Relationship between rheumatoid arthritis and periodontitis, J Periodontal,2001, No.72(6), pp.779-787
  • Mercado F.B., Marshall R.I., Klestov A.C., Bartold P.M. Is there a relationship between rheumatoid arthritis and periodontal disease? J Clin Periodontol, 2000, No.27(4), pp.267-272
  • Symmons D, Turner G, Webb R et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford), 2002, No.41. pp. 793- 800.
  • Kvien TK, Glennas A, Knudsrod OG et al. The prevalence and severity of rheumatoid arthritis in Oslo: results from a county register and a population survey, Scand J Rheumatol, 1997, No.26. pp. 412- 418.
  • Akar S, Birlik M, Gurler O et al. The prevalence of rheumatoid arthritis in an urban population of Izmir-Turkey, Clin Exp Rheumatol, 2004, No.22, pp. 416 -420.
  • Guillemin F, Saraux A, Guggenbuhl P et al. Prevalence of rheumatoid arthritis in France: 2001, Ann Rheum Dis, 2005, No.64. pp. 1427- 1430.
  • Spindler A, Bellomio V, Berman A et al. Prevalence of rheumatoid arthritis in Tucuman, Argentina, J Rheumatol, 2002, No.29. pp.1166- 1170.
  • Mjasoedova S.E., Lesnjak O.M., Men’shikova L.V. Rasprostranennost’ revmatoidnogo artrita v Rossii (po dannym jepidemiologicheskih issledovanij) (The prevalence of rheumatoid arthritis in Russia (according to epidemiological studies)), Terapevticheskij arhiv, 2010, No.82(5), pp.9–14.
  • Statisticheskij sbornik «Zdorov’e naselenija RK i dejatel’nost’ organizacij zdravoohranenija v 2011 godu» (Statistical Yearbook “Health of Kazakhstan and activities of health care organizations in 2011”), Astana, 2012.
  • Togizbaev G.A., Shamitekov I.M., Bermagambetova G.N. Rasprostranennost’ i social’naja znachimost’ revmatoidnogo artrita v Respublike Kazahstan. (Prevalence and social significance of rheumatoid arthritis in the Republic of Kazakhstan), Materialy I Evrazijskogo kongressa revmatologov, Almaty Respublika Kazahstan, 2012, pp.102-105
  • Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients, Arthritis Rheum, 2003, No.48, pp. 2750 – 2762.
  • Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford), 2000, No.39. pp. 28 – 33.
  • Afanas’ev I.A., Nikitina N.M., Rebrov A.P. Ocenka jeffektivnosti bazisnoj terapii revmatoidnogo artrita s pozicii koncepcii Treatto-target (Evaluating the effectiveness of the basic treatment of rheumatoid arthritis with pozitsii concept Treat-to-target), Materialy i tezisy І Evrazijskogo kongressa revmatologov, 2012, pp.14-15.
  • Weinblatt ME, Coblyn JS, Fox DA, Fraser PA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis, N Engl J Med, 1985, No.312(13), pp. 818 – 822.
  • Jundt JW, Browne BA, Fiocco GP et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing, J Rheumatol, 1993, No.20(11), pp. 1845 – 1849.
  • Hoekstra M, Haagsma C, Neef C, Proost J et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis, J Rheumatol, 2004, No.31(4), pp. 645 – 648.
  • Pichlmeier U, Heuer KU. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate, Clin Exp Rheumatol, 2014, No.32(4), pp. 563 – 571.
  • Hoekstra M, Haagsma C, Neef C, et al. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis, J Rheumatol, 2006, No.33, pp.481-485.
  • Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses >/=15 mg may be overcome with subcutaneous administration, Ann Rheum Dis, 2014, No.73(8), pp. 1549 – 1551.
  • Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial, Arthritis Rheum, 2008, No.58, pp. 73- 81.
  • Islam MS, Haq SA, Islam MN, Azad AK et al. Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis, Mymensingh Med J, 2013, No.22(3), pp. 483 – 488.
  • Murav’ev Ju.V., Denisov L.N., Alekseeva A.V., Murav’eva N.V., Nasonov E.L. et al. Otkrytoe kontroliruemoe randomizirovannoe 24-nedel’noe sravnitel’noe issledovanie in#ekcionnoj i tabletirovannoj lekarstvennyh form metotreksata pri revmatoidnom artrite (Open, controlled, randomized, 24-week comparative study of injectable and tablet formulations of methotrexate in rheumatoid arthritis), Nauchno-prakticheskaja revmatologija, 2011, No.5. pp. 58- 61.
  • Stamp LK, Barclay ML, O’Donnell JL, et al. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol, 2011, No.38. pp. 2540- 2547.
  • Crespo C, Brosa M, Galvan J, Carbonell J et al. Pharmacoeconomic analysis of Metoject (R) in the treatment of rheumatoid arthritis in Spain, Reumatol Clin, 2010, No.6(4), pp. 203- 211.
  • Scott D, Claydon P, Ellis C. Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study,Scand J Rheumatol, 2014, No. 5. pp. 1- 7.
  • Curtis JR, Zhang J, Xie F, Beukelman T. Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United States. Arthritis Care Res (Hoboken.),2014.